9th Cir. Reinstates Beovu Case Against Novartis, Finds Claims Not Preempted



DOCUMENTS
  • Order


LOS ANGELES — A federal appeals panel has reinstated a lawsuit targeting Novartis Pharmaceutical Corp.’s macular degeneration drug Beovu, ruling the claims are not preempted because the plaintiff sufficiently pled the existence of “newly acquired information” that would have allowed the drug maker to strengthen its warnings pursuant to the Changes Being Effected process.

In a March 18 opinion, the 9th Circuit U.S. Court of Appeals panel further ruled the fraud claims were sufficiently pled to the extent they are based upon the drug’s label.

Raymond Rayes was injected with Beovu (brolucizumab), a human vascular endothelial growth factor (“VEGF”) inhibitor, …

FIRM NAMES
  • Hollingsworth LLP
  • Levin Papantonio Rafferty
  • Paish Shea & Boyle
  • Parker Milliken Clark O'Hara





UPCOMING CONFERENCES




HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS



HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates

May 29, 2024 - Salt Lake City, UT
The Grand America Hotel

MORE DETAILS